Breast Cancer clinical trials in Montana

8 actively recruiting breast cancer trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed 2026-10-19

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Intermountain Health West End Clinic — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center — Butte, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05812807

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology

NCT ID: NCT04852887

Sites in Montana:

Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Community Medical Center — Missoula, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03418961

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Deaconess Hospital — Bozeman, Montana
Benefis Healthcare- Sletten Cancer Institute — Great Falls, Montana
Great Falls Clinic — Great Falls, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07391774

Sites in Montana:

Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Community Medical Center — Missoula, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…

Sponsor: ALX Oncology Inc.

NCT ID: NCT07007559

Sites in Montana:

St. Vincent Regional Hospital - Cancer Centers of Montana — Billings, Montana

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.

Sponsor: TerSera Therapeutics LLC

NCT ID: NCT07310420

Sites in Montana:

St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute) — Billings, Montana

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19